Ustekinumab

Results: 77



#Item
41The COMET Trial:  Clinical Results in Moderate to Severe RA

The COMET Trial: Clinical Results in Moderate to Severe RA

Add to Reading List

Source URL: www.dermatology.ca

Language: English - Date: 2014-06-09 11:19:25
42P4.30 CDA Langley PSOLAR Malignancies_v08_FINAL.PPTX

P4.30 CDA Langley PSOLAR Malignancies_v08_FINAL.PPTX

Add to Reading List

Source URL: www.dermatology.ca

Language: English - Date: 2014-07-30 15:52:43
43P4.31_Bissonnette_PSOLAR_MACE_CDA_v05_final.pptx

P4.31_Bissonnette_PSOLAR_MACE_CDA_v05_final.pptx

Add to Reading List

Source URL: www.dermatology.ca

Language: English - Date: 2014-07-30 15:52:46
44The COMET Trial:  Clinical Results in Moderate to Severe RA

The COMET Trial: Clinical Results in Moderate to Severe RA

Add to Reading List

Source URL: www.dermatology.ca

Language: English - Date: 2014-06-09 11:19:23
45PRIOR AUTHORIZATION POLICY Stelara™ (ustekinumab for subcutaneous [SC] injection – Centocor Ortho Biotech) To Initiate a Coverage Review, Call[removed]For Coverage Under the Medical Benefit, Call[removed]

PRIOR AUTHORIZATION POLICY Stelara™ (ustekinumab for subcutaneous [SC] injection – Centocor Ortho Biotech) To Initiate a Coverage Review, Call[removed]For Coverage Under the Medical Benefit, Call[removed]

Add to Reading List

Source URL: statehealthplan.state.nc.us

Language: English - Date: 2014-08-12 13:02:44
46PRIOR AUTHORIZATION POLICY Otezla® (apremilast tablets – Celgene Corporation) To Initiate a Coverage Review, Call[removed]OVERVIEW Otezla, a phosphodiesterase 4 (PDE4) inhibitor, is indicated for treatment of a

PRIOR AUTHORIZATION POLICY Otezla® (apremilast tablets – Celgene Corporation) To Initiate a Coverage Review, Call[removed]OVERVIEW Otezla, a phosphodiesterase 4 (PDE4) inhibitor, is indicated for treatment of a

Add to Reading List

Source URL: statehealthplan.state.nc.us

Language: English - Date: 2014-05-29 15:15:36
47HORMONE THERAPY PRESCRIPTION COMPOUNDS

HORMONE THERAPY PRESCRIPTION COMPOUNDS

Add to Reading List

Source URL: www.xubex.com

Language: English - Date: 2014-02-04 11:46:09
48Immunology / Etanercept / Biologic / Psoriasis / Ustekinumab / Alefacept / Adalimumab / Acitretin / Methotrexate / Immunosuppressants / Medicine / Pharmacology

RAPAM.12 Form # 20910 R: 12.13 State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form

Add to Reading List

Source URL: www.mainecarepdl.org

Language: English - Date: 2014-01-16 12:07:13
49Kansas Medical Assistance Program  P O Box 3571 Topeka, KS[removed]Provider[removed]Beneficiary[removed]

Kansas Medical Assistance Program P O Box 3571 Topeka, KS[removed]Provider[removed]Beneficiary[removed]

Add to Reading List

Source URL: www.kdheks.gov

Language: English - Date: 2014-01-31 15:34:30
50Current as of[removed]This document may not be part of the latest approved REMS.  Attachment C Journal Information Piece for Dermatologists STELARA® (ustekinumab) is a human monoclonal antibody that is indicated for t

Current as of[removed]This document may not be part of the latest approved REMS. Attachment C Journal Information Piece for Dermatologists STELARA® (ustekinumab) is a human monoclonal antibody that is indicated for t

Add to Reading List

Source URL: www.fda.gov

Language: English